KCT0001120招募中未知
Phase 1/2 Clinical Study to Evaluate Safety and Efficacy of Allogenic Adipose-derived Stem Cells(ALLO-ASC-TI) for the Treatment of Patients With Lateral Epicondylalgia: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study
Anterogen0 个研究点目标入组 27 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Older than 19 years.
- •2.Patients who are diagnosed as lateral epicondylitis (Pain=4 of VAS during activity).
- •3.Patients who has sustained pain more than 6 months
- •4.Patients who lasting for pain in spite of conservative therapy
- •5.Patients who have one lesion under ultrasonic photography
- •6.Negative for urine beta-HCG for women of childbearing age
- •7.Patient who is able to give written informed consent prior to study start and to comply with the study requirements
排除标准
- •1.Patients who has been experienced steroid and prolotherapy or other treatment within 3 months at screening time
- •2.Patients who have lesion size of width and length more than 1 cm using ultrasonic photography test
- •3.Patients who were accompanied by the disease as follows: A. Arthritis of related joint to the target lesiom (ex, cubital osteo- arthritis), B.Synovitis of related joint to the target lesion, C.Entrapment of related nerve to the target lesion(ex, radial tunnel syndrome), D.Generalized pain syndrome, E.Radiculopathy related to the target lesion(ex, cervical spodylosis ,cervical radicular syndrome), F.Rheumatoid arthritis, G.Previous fracture of arm causing limitations in arm function, H.Impaired sensibility, I.Paralysis
- •4.Patients who are pregnant or breast-feeding
- •5.Patients who have allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue
- •6.Patients who have history of fracture and dislocation at Ipsilateral upper extremity within 2 years recently
- •7.Patients who have operation history in tendon, ligament and bone at Ipsilateral upper extremity within 2 years recently
- •8.Patients who are unwilling to use an effective method of contraception during the study
- •9.Patients who have a clinically relevant history of abuse of alcohol or drugs
- •10.Patients who are considered not suitable for the study by investigator
- •11.Patients who have experienced treatment with stem cell before this study
- •12.Patients who currently enrolled in another investigational drug study within 30 days of screening
研究者
相似试验
进行中（未招募）
1 期
A phase 1/2 clinical trial to assess safety and efficacy of a new treatment for Hodgkin lymphoma's disease combining Adcetris¿ and Levact¿ in Old patientsMedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 100000004864Hodgkin LymphomaEUCTR2014-003320-51-ITCENTRE ANTOINE LACASSAGNE60
已完成
不适用
A clinical phase II study assessing the safety and efficacy of readministration of bendamustine monotherapy or bendamustine/rituximab for relapsed low grade B cell non-Hodgkin lymphoma or mantle cell lymphoma patients previously treated with bendamustine containing chemothearpylow-grade B cell non-Hodgkin lymphoma, Mantle cell lymphomaJPRN-UMIN000010923KEIO BRB Study Group38
招募中
2 期
A Phase 2 Study of MK-3475A in Japanese Participants with Recurrent or Metastatic (R/M) or Locally Advanced (LA) unresectable Cutaneous Squamous Cell Carcinoma (cSCC)JPRN-jRCT2041230074Koh Yasuhiro19
进行中（未招募）
不适用
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung CancerAdvanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following one or more chemotherapy regimens.MedDRA version: 8.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2006-002830-38-DEAbbott GmbH & Co. KG180
进行中（未招募）
不适用
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2006-002830-38-NLAbbott GmbH & Co. KG180